ValuEngine Upgrades Zynerba Pharmaceuticals (NASDAQ:ZYNE) to “Buy”

Zynerba Pharmaceuticals (NASDAQ:ZYNE) was upgraded by investment analysts at ValuEngine from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Friday, May 17th, ValuEngine reports.

ZYNE has been the subject of a number of other research reports. Roth Capital began coverage on shares of Zynerba Pharmaceuticals in a report on Tuesday, April 30th. They set a “buy” rating and a $36.00 price target for the company. Canaccord Genuity initiated coverage on shares of Zynerba Pharmaceuticals in a research report on Monday, April 22nd. They set a “buy” rating and a $8.09 price objective for the company. Cantor Fitzgerald reiterated a “buy” rating and set a $11.00 price objective on shares of Zynerba Pharmaceuticals in a research report on Thursday, March 7th. HC Wainwright reiterated a “buy” rating on shares of Zynerba Pharmaceuticals in a

... read more at: https://techknowbits.com/2019/06/10/zynerba-pharmaceuticals-zyne-upgraded-to-buy-at-valuengine.html